Abstract: A compound having a hypoglycemic effect is provided. The compound and a pharmaceutically acceptable salt thereof are useful for the treatment or prevention of diabetes, obesity, and the like. The compound is represented by the general formula (1): (wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a C1 to C6 alkylsulfanyl group, a C1 to C6 alkylsulfinyl group, a C1 to C6 alkylsulfonyl group, or a C1 to C6 alkoxy-C1 to C6 alkylsulfonyl group, and A is a substituted or unsubstituted heteroaryl group).

Abstract: Process for obtaining formic acid by thermal separation of a stream comprising formic acid and a tertiary amine (I), in which, in step (a), a liquid stream comprising formic acid, methanol, water and tertiary amine (I) is produced by combining methyl formate, water and tertiary amine (I), from there in step (b), methanol is separated off and in step (c), formic acid is removed by distillation from the liquid stream obtained in a distillation apparatus, wherein, when methyl formate, water and tertiary amine (I) are combined, methyl formate, water and optionally tertiary amine (I) are first introduced in step (a1) in a molar ratio of 0?n(amine to a1)/n(mefo to a1)?0.1, and from 70 to 100% of the hydrolysis equilibrium possible is set and then, in step (a2), tertiary amine (I) is introduced in a molar ratio of 0.1?n(amine to a2)/n(mefo to a1)?2, and the mixture is reacted.

Abstract: A method for manufacturing a water resistant optically anisotropic film capable of suppressing the generation of a defect such as a crack or separation is provided. The method for manufacturing the water resistant optically anisotropic of the present invention includes a water resistant treatment step of bringing an optically anisotropic film containing an organic dye having an anionic group into contact with a water resistant treatment liquid containing a multivalent cationic compound and a monovalent cationic compound, and the mass ratio of the multivalent cationic compound and the monovalent cationic compound contained in the water resistant treatment liquid, monovalent cationic compound/multivalent cationic compound, is 0.01 to 2.

Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Abstract: The present invention relates to novel non-aqueous gels of natural oils and their derivatives and provides a novel process for the gelation of natural oils and their derivatives that does not require the addition of gellants or the irreversible heat bodying of the oil. The gels and method of the present invention are applicable to a wide range of natural oils, and the method is easily tailored to provide thermoreversible gels of any desired viscosity. The natural oil based gels of the present invention and the method of their preparation have many advantages over the prior art. The natural oil based gels provided have exemplary properties and find use in a variety of applications.

Abstract: The invention provides a method for preparing a succinic acid, which method includes the steps of: providing magnesium succinate; acidifying the magnesium succinate with hydrochloric acid (HCl), thereby obtaining a solution including succinic acid and magnesium chloride (MgCl2); optionally a concentration step, wherein the solution including succinic acid and MgCl2 is concentrated; precipitating succinic acid from the solution including succinic acid and MgCl2, thereby obtaining a succinic acid precipitate and a MgCl2 solution. The addition of HCl to a magnesium salt of succinic acid and subsequent precipitation of succinic acid from the solution leads to a very efficient separation of succinic acid from a magnesium succinate solution.

Abstract: The present invention provides a diaryl sulfone compound represented by Formula (1): wherein R1 to R4 and R1? to R4? are the same or different, and each represents hydrogen, C1-4 alkyl, or halogen, and R5 represents C2-6 alkenyl, C1-4 alkyl, or aromatic heterocyclic group; a method for producing the diaryl sulfone compound represented by Formula (1) by reacting a 4,4?-dihaloarylsulfone compound with thiol salt compound having an alkylene group; and a method for producing the diaryl sulfone compound represented by Formula (1) by reacting a 4,4?-dihaloarylsulfone compound with a thiol salt compound having a hydroxyl group, and subjecting the resulting compound to reaction with a halogenating agent, followed by a dehydrohalogenation reaction.

Abstract: The present invention is directed to the separation of ethanol from a crude ethanol product obtained from the vaporization and hydrogenation of acetic acid using reduced residence time for the vapor phase reactants between exiting the vaporizer and entering the reactor. The crude ethanol product is separated in at least one column to recover an ethanol product.

Abstract: This invention provides methods for producing ethylene glycol from polyhydroxy compounds such as cellulose, starch, hemicellulose, glucose, sucrose, fructose, fructan, xylose and soluble xylooligosaccharides. The methods uses polyhydroxy compounds as the reactant, a composite catalyst having active components comprising one or more transition metals of Groups 8, 9, or 10, including iron, cobalt, nickel, ruthenium, rhodium, palladium, iridium, and platinum, as well as tungsten oxide, tungsten sulfide, tungsten hydroxide, tungsten chloride, tungsten bronze oxide, tungsten acid, tungstate, metatungstate acid, metatungstate, paratungstate acid, paratungstate, peroxotungstic acid, pertungstate, heteropoly acid containing tungsten. Reacting at a temperature of 120-300° C. and a hydrogen pressure of 1-13 MPa under hydrothermal conditions to accomplish one-step catalytic conversion. It realizes efficient, highly selective, high yield preparation of ethylene glycol and propylene glycol from polyhydroxy compounds.

Abstract: A salt represented by the formula (X): wherein Q1 and Q2 each independently represent a fluorine atom etc., L1 and L2 independently each represent a C1-C17 divalent saturated hydrocarbon group, ring W1 represents a C3-C36 saturated hydrocarbon ring, R2 is independently in each occurrence a hydroxyl group etc., s represents an integer of 0 to 2, Z+ represents an organic counter ion, and W10 represents a group represented by the formula (X-1): wherein ring W2 represents a C4-C36 saturated hydrocarbon ring in which one or more —CH2— can be replaced by —O— or —CO—, with the proviso that at least one —CH2— in the C4-C36 saturated hydrocarbon ring is replaced by —CO—, R3 is independently in each occurrence a C1-C6 alkyl group etc., and t represents an integer of 0 to 2, or a group represented by the formula (X-2): wherein ring W3 represents a C3-C36 saturated hydrocarbon ring, R4 is independently in each occurrence a hydroxyl group etc., R5 is independently in each occurrence a C1-C6 alkyl group etc.

Abstract: The invention provides isoquinoline, quinoline, and quinazoline derivatives to treat a variety of disorders, diseases and pathologic conditions, and more specifically to the use of isoquinoline, quinoline, and quinazoline derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds to the treatment of hyperproliferative diseases and pathologic angiogenesis.

Abstract: The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Abstract: This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

Abstract: Process for preparing bicyclic or tricyclic (meth)acrylates by reacting (meth)acrylic acid with a bicyclic or tricyclic hydrocarbon which contains at least one double bond using montmorillonite as catalyst.

Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Abstract: A method that manufacturers an optically active carboxylic acid ester at high yield and high enantioselectivity is provided. An optically active carboxylic acid ester is manufactured at high yield and high enantioselectivity by reacting a racemic carboxylic acid and a specific alcohol or phenol derivatives in a polar solvent having a dipole moment of 3.0 or higher in the presence of an acid anhydride and an asymmetric catalyst, esterifying one enantiomer of the racemic carboxylic acid at high selectivity, and increasing the amount of esterified carboxylic acid by racemizing the optically active carboxylic acid which is the other enantiomer not used in esterification.

Abstract: Disclosed herein are novel C4-monomethyl triterpenoid compounds and derivatives thereof, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.

Abstract: An arylamine compound including: a partial structure shown in formula (1-1) or (1-2), wherein either X or Y is one of leaving substituents and the other is a hydrogen atom; either (X1, X2) or (Y1, Y2) is one of the leaving substituents respectively and the other is the hydrogen atom respectively; each of Q1, Q2, Q3, Q4, Q5, and Q6 is selected from the hydrogen atom, a halogen atom, organic substituents other than the leaving substituents, and an atomic bonding to link with an adjacent arylamine group respectively; and adjacent two substituents selected from Q1, Q2, Q3, Q4, Q5, and Q6 may be linked together to form the ring which may be a part of an arylamine group.

Abstract: Disclosed are naphtho[2,3-f]quinoxaline compounds and pharmaceutical composition thereof. The compounds of the invention have been demonstrated as having analgesic effects and therefore may be applicable for use as a novel agent in relieving acute or chronic pain.

Abstract: The present disclosure provides compounds of general formula A: useful as potential anti-tubercular agents.